ArticleOncoimmunology
Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Proteoglycans in Breast Cancer: Friends and Foes.Biomolecules · 2025Review
- Molecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression.Glycoconjugate journal · 2025Article
- Glycosaminoglycans Targeted by Colchicine in MCF-7 Cells.Pharmaceutics · 2025Article
- Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma.Journal of translational medicine · 2023Article
- Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy.Oncoimmunology · 2023Article
- Biglycan Promotes Cancer Stem Cell Properties, NFκB Signaling and Metastatic Potential in Breast Cancer Cells.Cancers · 2022Article
- Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.Oncoimmunology · 2022Article
- Mechanical Pressure Driving Proteoglycan Expression in Mammographic Density: a Self-perpetuating Cycle?Journal of mammary gland biology and neoplasia · 2021Review
- Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.Cancer discovery · 2021Article
- Identification of a novel miR-21-3p/TGF-β signaling-driven immune escape via the MHC class I/biglycan axis in tumor cells.Clinical and translational medicine · 2021Article
- The Role of Decorin and Biglycan Signaling in Tumorigenesis.Frontiers in oncology · 2021Review
- Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy.Frontiers in oncology · 2021Article
- Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy?Frontiers in cell and developmental biology · 2021Review
- LUM Expression and Its Prognostic Significance in Gastric Cancer.Frontiers in oncology · 2020Article
- Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.Cancer immunology, immunotherapy : CII · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extracellular matrix protein biglycan (BGN) has oncogenic or tumor suppressive potential depending on the cellular origin. HER-2/neu overexpression in murine fibroblasts and human model systems is inversely correlated with BGN expression. Upon its restoration BGN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.